UB Paderborn / Katalog / Suche / in CDI

1 – 13 von 13

Sortiert nach

Concentrations of Galectin-3 in the Sera of Normal Controls and Cancer Patients

Clinical cancer research, 2000-04, Vol.6 (4), p.1389-1393

2000

Volltextzugriff (PDF)

Improved tumor control through circadian clock induction by seliciclib, a cyclin-dependent kinase inhibitor

Cancer research (Chicago, Ill.), 2006-11, Vol.66 (22), p.10720-10728

2006

Volltextzugriff (PDF)

Synthetic Inhibitors of Galectin-1 and -3 Selectively Modulate Homotypic Cell Aggregation and Tumor Cell Apoptosis

Anticancer research, 2009-01, Vol.29 (1), p.403-410

2009

Volltextzugriff (PDF)

90K (Mac-2 BP) and galectins in tumor progression and metastasis

Glycoconjugate journal, 2002, Vol.19 (7-9), p.551-556

2002

Volltextzugriff (PDF)

The circadian rest‐activity rhythm, a potential safety pharmacology endpoint of cancer chemotherapy

International journal of cancer, 2014-06, Vol.134 (11), p.2717-2725

2014

Volltextzugriff (PDF)

LIVER CIRCADIAN CLOCK, A PHARMACOLOGIC TARGET OF CYCLIN-DEPENDENT KINASE INHIBITOR SELICICLIB

Chronobiology international, 2009-08, Vol.26 (6), p.1169-1188

2009

Volltextzugriff (PDF)

Impact on treatment adherence, side effects control, patients QoL, and rehospitalization rate through new management of oral chemotherapy

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.e18533-e18533

2018

Volltextzugriff (PDF)

Synthetic lactulose amines: novel class of anticancer agents that induce tumor-cell apoptosis and inhibit galectin-mediated homotypic cell aggregation and endothelial cell morphogenesis

Glycobiology (Oxford), 2006-03, Vol.16 (3), p.210-220

2006

Volltextzugriff (PDF)

Clock genes expression in breast cancers (BC) from patients (pts) treated with neoadjuvant chemotherapy (NAC) in a randomized multicenter phase II trial

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.e11528-e11528

2014

Volltextzugriff (PDF)

Surgical management of Low-Grade Serous Carcinoma of the ovary: Results of a multicenter study from The French National Network dedicated to Ovarian Malignant Rare Tumors (TMRO)

European journal of obstetrics & gynecology and reproductive biology, 2019-03, Vol.234, p.e143-e144

2019

Volltextzugriff (PDF)

Liver circadian clock, a pharmacologic target of cyclin-dependent kinase inhibitor seliciclib

Chronobiology international, 2009-08, Vol.26 (6), p.1169-1188

2009

Volltextzugriff (PDF)

Relief of symptoms after gefitinib is associated with improvement of rest/activity rhythm in advanced lung cancer

Journal of clinical oncology, 2007-06, Vol.25 (16), p.e17-e19

2007

Volltextzugriff (PDF)

Effects of cyclin-dependent kinase inhibitor R-Roscovitine (Cyc202) on clock and cell cycle genes expression patterns. Relation with antitumor efficacy

Pathologie biologie (Paris), 2007-04, Vol.55 (3), p.213-214

2007

Volltextzugriff (PDF)

1 – 13 von 13

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(13)
Mit Volltextzugriff
(13)

Publikationsform

Artikel
(13)

Sprache

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(8)
Science & Technology
(8)
Humans
(6)
Oncology
(5)
Tumors
(4)
Antigens, Neoplasm
(3)
Antineoplastic Agents - Pharmacology
(3)
Apoptosis
(3)
Biological And Medical Sciences
(3)
Biomarkers, Tumor
(3)
Circadian Rhythm
(3)
Male
(3)
Medical Sciences
(3)
Neoplasms - Pathology
(3)
Animals
(2)
Apoptosis - Drug Effects
(2)
Biochemistry & Molecular Biology
(2)
Cancer
(2)
Carrier Proteins - Metabolism
(2)
Cell Aggregation - Drug Effects
(2)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Concentrations of Galectin-3 in the Sera of Normal Controls and Cancer Patients

Improved tumor control through circadian clock induction by seliciclib, a cyclin-dependent kinase inhibitor

Synthetic Inhibitors of Galectin-1 and -3 Selectively Modulate Homotypic Cell Aggregation and Tumor Cell Apoptosis

90K (Mac-2 BP) and galectins in tumor progression and metastasis

The circadian rest‐activity rhythm, a potential safety pharmacology endpoint of cancer chemotherapy

LIVER CIRCADIAN CLOCK, A PHARMACOLOGIC TARGET OF CYCLIN-DEPENDENT KINASE INHIBITOR SELICICLIB

Impact on treatment adherence, side effects control, patients QoL, and rehospitalization rate through new management of oral chemotherapy

Synthetic lactulose amines: novel class of anticancer agents that induce tumor-cell apoptosis and inhibit galectin-mediated homotypic cell aggregation and endothelial cell morphogenesis

Clock genes expression in breast cancers (BC) from patients (pts) treated with neoadjuvant chemotherapy (NAC) in a randomized multicenter phase II trial

Surgical management of Low-Grade Serous Carcinoma of the ovary: Results of a multicenter study from The French National Network dedicated to Ovarian Malignant Rare Tumors (TMRO)

Liver circadian clock, a pharmacologic target of cyclin-dependent kinase inhibitor seliciclib

Relief of symptoms after gefitinib is associated with improvement of rest/activity rhythm in advanced lung cancer

Effects of cyclin-dependent kinase inhibitor R-Roscovitine (Cyc202) on clock and cell cycle genes expression patterns. Relation with antitumor efficacy

Suchergebnisse filtern